Targeting 14-3-3ε-CDC25A interactions to trigger apoptotic cell death in skin cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Non-melanoma skin cancer, particularly cutaneous squamous cell carcinoma (SCC), is a prevalent global health concern.
• The protein CDC25A plays an anti-apoptotic role in SCC, mediated by its interaction with 14-3-3 proteins.

Purpose of the Study:

• To investigate the potential of targeting the CDC25A-14-3-3ε interaction as a therapeutic strategy for inducing apoptosis in skin cancer cells.
• To develop and evaluate novel phospho-peptides designed to disrupt this specific protein-protein interaction.

Main Methods:

• Co-immunoprecipitation assays were used to confirm the association of CDC25A with 14-3-3 isoforms (ε, γ, ζ) in SCC cells.
• Development of two phospho-peptides (pS and pT) mimicking CDC25A's 14-3-3 binding sites.
• In vitro and in vivo studies using SCC cell lines and xenografts to assess peptide efficacy.

Main Results:

• CDC25A was found to associate with 14-3-3ε, γ, and ζ in SCC cells, activating pro-survival signaling pathways (Akt/BAD/Survivin).
• The developed peptides, pS and pT, effectively blocked 14-3-3ε binding to CDC25A and induced SCC cell death.
• In vivo administration of pS or pT to SCC xenografts resulted in increased apoptosis and reduced levels of pro-survival markers.

Conclusions:

• Targeting the CDC25A-14-3-3ε interaction with specific phospho-peptides is a viable therapeutic approach for skin cancer.
• These findings provide a foundation for developing peptide-based therapies to treat non-melanoma skin cancers by disrupting critical survival pathways.